What is whole exome sequencing and when is it useful for cancer
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Whole Exome Sequencing (WES) in Cancer Care
What Is Whole Exome Sequencing?
Whole exome sequencing is a genetic test that reads the DNA code of all the genes that actually produce proteins in your body—called the "exome." Think of your DNA as a massive instruction manual: the exome is the part that contains the actual recipes for making proteins, while the rest of the DNA contains regulatory instructions and other information.
In cancer care, WES sequences the tumor's DNA (not your normal cells), looking for mutations—changes in the genetic code—that are driving the cancer growth.
How It Works
- Sample collection: A tissue sample from your tumor is sent to the lab
- DNA extraction: Scientists isolate the tumor's DNA
- Sequencing: Advanced machines read through all ~20,000 protein-coding genes
- Analysis: Computers identify mutations and compare them to databases of known cancer-related changes
- Report: You receive a list of mutations found in your specific tumor
When WES Is Useful for Cancer Patients
WES is most valuable when:
- Standard tests don't explain your cancer: If your tumor doesn't have common mutations (like EGFR, BRAF, or HER2), WES can cast a wider net to find what's driving it
- You have a rare cancer type: Uncommon cancers may not have established biomarker tests, making comprehensive sequencing more helpful
- You're considering clinical trials: Many research studies require detailed genetic information about your tumor
- Your cancer has unusual features: If it's aggressive, appeared at an unusual age, or behaves unexpectedly, WES can help explain why
- Targeted therapy options might exist: Finding specific mutations can open doors to precision medicines designed to attack those exact changes
Comparison to Other Genetic Tests
| Test Type | What It Covers | Best For | |-----------|---|---| | Single gene test (e.g., EGFR, BRAF) | 1-2 specific genes | Common cancers with known mutations | | Panel testing | 50-500 genes | Targeted approach; faster results | | Whole exome sequencing | ~20,000 genes | Comprehensive search; rare mutations |
Important Context
According to NCCN (National Comprehensive Cancer Network) Guidelines, tumor genetic testing is now standard for many cancer types. WES is increasingly used when:
- Targeted therapy options might apply to your specific cancer
- You're exploring precision medicine approaches
- Standard panels haven't identified actionable mutations
The American Cancer Society emphasizes that genetic testing helps oncologists match patients with treatments most likely to work against their specific tumor.
Key Questions to Ask Your Oncologist
If WES is being considered for you:
- "Does my cancer type typically benefit from whole exome sequencing, or would a targeted panel be sufficient?"
- "What will we do with the results—are there specific treatments or clinical trials this might open up for me?"
- "How long will results take, and will you help me understand what they mean?"
- "Are there any variants of uncertain significance (VUS) in my results, and what does that mean?"
- "Will insurance cover this test, or what are the costs?"
Important Limitations
- Not all mutations are actionable: Finding a mutation doesn't always mean there's a treatment for it
- Incidental findings: WES might identify mutations unrelated to your cancer
- Variants of uncertain significance: Some mutations' importance isn't yet understood
- Results require expert interpretation: Your oncologist needs to determine which findings are clinically relevant to YOUR case
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2
It is h3k27 altered dmg h3k27m negative, egfr a289v myc tp53 mgmt methylated
Your tumor has specific genetic changes H3K27, EGFR, MYC, TP53, MGMT that your doctors will use to guide treatment decisions—these findings help deter